1.06
price up icon11.24%   0.1071
after-market アフターアワーズ: 1.06
loading

Ocugen Inc (OCGN) 最新ニュース

pulisher
03:51 AM

Ocugen Secures Licensing Agreement for OCU400 in Korea - MSN

03:51 AM
pulisher
Jun 05, 2025

Ocugen Signs License Agreement for OCU400 in Korea - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | OCGN Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene ... - Bluefield Daily Telegraph

Jun 05, 2025
pulisher
Jun 05, 2025

OCGNOcugen Provides Business Update with First Quarter 2025 Financial Results - mx.advfn.com

Jun 05, 2025
pulisher
Jun 02, 2025

Malvern-Based Ocugen to Pursue Rare Pediatric Disease Therapy - VISTA.Today

Jun 02, 2025
pulisher
Jun 01, 2025

Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN

Jun 01, 2025
pulisher
May 31, 2025

Ocugen Receives Rare Pediatric Disease Designation for OCU410ST - MSN

May 31, 2025
pulisher
May 29, 2025

FDA awards Ocugen drug with Rare Pediatric Disease Designation - Pennsylvania Business Report -

May 29, 2025
pulisher
May 28, 2025

Ocugen’s Gene Therapy OCU410ST Nets Rare Pediatric Disease Designation for ABCA4-Associated Retinopathies - CGTLive®

May 28, 2025
pulisher
May 28, 2025

Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment - MSN

May 28, 2025
pulisher
May 27, 2025

FDA grants Ocugen rare pediatric disease designation as voucher program remains in limbo - The Business Journals

May 27, 2025
pulisher
May 27, 2025

Ocugen Gets FDA Rare Pediatric Disease Label for OCU410ST - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Ocugen (OCGN) Gains Rare Pediatric Disease Status for Eye Therap - GuruFocus

May 27, 2025
pulisher
May 27, 2025

FDA grants Ocugen’s OCU410ST rare pediatric disease status By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease - Ocugen

May 27, 2025
pulisher
May 27, 2025

Ocugen Announces Rare Pediatric Disease Designation Granted for - GuruFocus

May 27, 2025
pulisher
May 27, 2025

FDA grants Ocugen’s OCU410ST rare pediatric disease status - Investing.com Australia

May 27, 2025
pulisher
May 27, 2025

FDA Grants Rare Pediatric Disease Designation to OCU410ST from Ocugen (OCGN) | OCGN Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Ocugen receives Rare Pediatric Disease Designation for OCU410ST - TipRanks

May 27, 2025
pulisher
May 27, 2025

Ocugen Announces Rare Pediatric Disease Designation Granted - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood BlindnessNo Current Treatment Exists - Stock Titan

May 27, 2025
pulisher
May 27, 2025

Northern Trust Corp Acquires 227,150 Shares of Ocugen, Inc. (NASDAQ:OCGN) - Defense World

May 27, 2025
pulisher
May 20, 2025

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish - MSN

May 20, 2025
pulisher
May 19, 2025

Ocugen, Inc. (NASDAQ:OCGN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

May 19, 2025
pulisher
May 16, 2025

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN

May 16, 2025
pulisher
May 16, 2025

Tower Research Capital LLC TRC Has $32,000 Position in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

May 16, 2025
pulisher
May 15, 2025

Ocugen Provides Business Update with First Quarter 2025 Financial Results - ADVFN

May 15, 2025
pulisher
May 15, 2025

Noble Financial Predicts Ocugen’s Q2 Earnings (NASDAQ:OCGN) - Defense World

May 15, 2025
pulisher
May 14, 2025

Ocugen to Host Q1 2025 Earnings Call and Business Update on May 9 - MSN

May 14, 2025
pulisher
May 13, 2025

Ocugen stock price target cut to $7 by H.C. Wainwright - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Ocugen (NASDAQ:OCGN) Receives Buy Rating from Chardan Capital - Defense World

May 13, 2025
pulisher
May 12, 2025

Ocugen (OCGN) Receives Ongoing "Buy" Rating from Chardan Capital - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Ocugen (OCGN) Maintains 'Buy' Rating Despite Price Target Adjust - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Ocugen (OCGN) Price Target Reduced by H.C. Wainwright | OCGN Sto - GuruFocus

May 12, 2025
pulisher
May 12, 2025

The Analyst Verdict: Ocugen In The Eyes Of 5 Experts - Benzinga

May 12, 2025
pulisher
May 12, 2025

Ocugen outlines 2025 milestones for gene therapy programs with BLA filings on track - MSN

May 12, 2025
pulisher
May 11, 2025

Barclays PLC Decreases Holdings in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

May 11, 2025
pulisher
May 10, 2025

Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 10, 2025

Ocugen: Q1 Earnings Snapshot - New Haven Register

May 10, 2025
$1.15
price up icon 0.00%
$585.93
price up icon 0.92%
$300.83
price down icon 2.33%
$38.11
price up icon 4.30%
$4.73
price down icon 1.69%
$493.22
price up icon 2.10%
大文字化:     |  ボリューム (24 時間):